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Low serum lymphocyte level 
is associated with poor exercise 
capacity and quality of life 
in chronic obstructive pulmonary 
disease
Sung Woo Moon1, Ah Young Leem1, Young Sam Kim1, Ji‑Hyun Lee2, tae‑Hyung Kim3, 
Yeon‑Mok oh4, Hyejung Shin5, Joon chang1, Ji Ye Jung1* & KoLD Study Group
the purpose of this study was to evaluate the association of serum lymphocyte level with several 
clinical parameters in COPD. The study population included 451 COPD patients from the Korean 
obstructive Lung Disease cohort study. Serum lymphocyte level was measured every year along 
with various clinical parameters, such as lung function, 6-min walking (6 MW) distance, quality of 
life using COPD assessment test (CAT) and St. George’s Respiratory Questionnaire (SGRQ) scores, 
exacerbations, and survival. Serum lymphocyte level less than 20% was considered as a low 
lymphocyte level. Normal lymphocyte and low lymphocyte groups comprised of 409 (90.7%) and 42 
(9.3%) patients, respectively. Clustered analysis showed that patients in low lymphocyte group had 
a lower post-bronchodilator forced expiratory volume in 1 s % predicted (estimated mean =  − 5.70%; 
P = 0.001), a lower forced vital capacity % predicted (estimated mean =  − 5.63%; P = 0.005), a shorter 
6 MW distance (estimated mean =  − 41.31 m; P < 0.001), a higher CAT score (estimated mean = 2.62; 
P = 0.013), and a higher SGRQ score (estimated mean = 10.10; P < 0.001). Serum lymphocyte level was 
not associated with frequent acute exacerbations nor mortality. Low serum lymphocyte group showed 
poorer pulmonary function, lower 6 MW distance, and worse quality of life. Serum lymphocyte levels 
could be a simple and widely available predictive marker for variable clinical outcomes in copD 
patients.
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by persistent air-
flow limitation and increased inflammatory  responses1,2. In the pathogenesis of COPD, chronic inflammation of 
the airways and the lung parenchyma has a critical role resulting goblet cell proliferation, glandular hyperplasia, 
fibrosis, collapse of the small airways, and parenchymal  destruction3. However, evidences are increasing that 
COPD also results in systemic inflammation and extra-pulmonary  manifestations4.
In several studies, it has been suggested that patients with COPD have increased levels of serum inflamma-
tory  markers5–7. Up to 70% of patients with COPD have at least one elevated serum inflammatory  parameter6. 
However, use of common plasma measures and biomarkers such as procalcitonin, C-reactive protein, and white 
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blood cell count, in routine clinical practice has limitations because of their low reproducibility to predict the 
prognosis in patients with  COPD8.
Although lymphocytes play a critical role in the pathogenesis of COPD involving airway and parenchymal 
inflammation, patients with COPD have also shown a decreased in lymphocyte  counts8–11. Low lymphocyte 
count is one of the markers of stress response and the low ratio of lymphocyte in the peripheral blood have the 
potential to indicate the pathological condition of chronic  inflammation8,10. A relatively low lymphocyte count is 
known to as a negative prognostic factor in patients with stable coronary heart disease, congestive heart failure, 
acute myocardial infarction, and the elderly  population12–15.
However, the role of serum lymphocyte level has not been fully validated in patients with COPD. Prediction 
of risk for various clinical outcomes with this simple serum measurement should be useful in clinical  practice16. 
This study aimed to investigate the association of repeatedly and simultaneously measured serum lymphocyte 
level with various clinical parameters including pulmonary function, exercise capacity, quality of life (QOL), 
exacerbation, and survival in a Korean COPD cohort study.
Methods
Study subjects. From the patients enrolled in the Korean Obstructive Lung Disease (KOLD) study, this 
study evaluated 451 patients with COPD. The KOLD cohort study enrolled patients over 18 years-of-age with 
COPD or asthma from 17 hospitals in South Korea between 2005 and  201517,18. The inclusion criteria were 
as follows: post-bronchodilator ratio of forced expiratory volume in 1  s to forced vital capacity  (FEV1/FVC) 
of < 0.7, > 40 years of age, smoking history of ≥ 10 pack-years, and no or minimal abnormality other than typical 
findings of COPD (such as bullous change, hyperinflation, emphysema, increased bronchovascular markings, 
etc.) on chest  radiography2,17,18. Patients with respiratory diseases other than obstructive lung disease (e.g., pre-
vious pulmonary resection, tuberculosis-destroyed lung, and bronchiectasis) and those with a recent (8 weeks 
before screening) exacerbation or other respiratory illness (such as upper respiratory infection or pneumo-
nia) were  excluded17,18. However, patients who recovered from an exacerbation and had been stable for more 
than 8 weeks were included in the study. After an initial enrollment visit, the patients were followed up every 
3 months and demographics data, pulmonary function test, St. George’s Respiratory Questionnaire (SGRQ), 
and 6-min walking (6 MW), and laboratory test were collected or performed every year in a stable condition for 
a least 4  weeks17,18. Acute exacerbations were assessed monthly through telephone contact and questionnaires 
every 3 months during hospital  visit17,18.
Assessment tests. The percentage of lymphocytes was defined as: (total lymphocytes / total leuko-
cytes) × 100. In our laboratories, the normal range of the lymphocyte percentage is 20 to 51%. Patients with a 
serum lymphocyte percentage < 20% were assigned to the low lymphocyte group and those with a serum lym-
phocyte percentage of 20–51% were assigned to the normal lymphocyte group.
The low and normal lymphocyte groups were compared using different assessment tools: pulmonary function 
tests, the 6-min walking (6 MW) distance, QOL as measured by the COPD Assessment Test (CAT) and the St. 
George’s Respiratory Questionnaire (SGRQ), exacerbations, and mortality. All assessments were repeated every 
year with a simultaneous measurement of the lymphocyte percentage. The 6 MW distance was measured on a 
20-m walking  course19. Exacerbation was defined as aggravation of one of three symptoms (dyspnea, cough, or 
sputum) for 2 or more days requiring an unscheduled hospital visit for additional treatment of systemic steroid 
or antibiotics, emergency room visit, or hospitalization. Frequent exacerbation was defined as having two or 
more exacerbations per year. Death and the cause of death were assessed during follow-up period.
Statistical methods. Student’s t test was used to compare continuous variables, whereas Pearson’s χ2 test 
was used to compare categorical variables between the low lymphocyte and normal lymphocyte groups. Data 
were presented as means ± standard deviation and numbers (percentage).
We assessed the relationship of the serum lymphocyte percentage with lung function, the 6 MW distance, 
QOL, exacerbation, and the survival in patients with COPD. Both the serum lymphocyte percentage and clinical 
outcomes were measured at the same time every year. Two effects of the serum lymphocyte percentage on repeat-
edly measured outcomes were analyzed: the effect of baseline level and the effect of overall level. First, to assess 
how the baseline serum lymphocyte percentage affected repeatedly measured continuous longitudinal datasets 
of lung function, 6 MW distance, dyspnea, and QOL, we conducted analysis of linear mixed model (LMM)20. 
To assess how the baseline serum lymphocyte percentage affected dichotomous longitudinal datasets of exacer-
bations, we conducted analysis of generalized estimating  equations21. Second, we conducted clustered analysis 
to assess how the overall level of serum lymphocyte percentage including the baseline level affected repeatedly 
measured clinical outcomes at the same time. In contrast to the first approach, we considered all repeated serum 
lymphocyte percentage measurements.
To investigate the relationship between serum lymphocyte percentage and mortality, multivariable Cox pro-
portional hazard models were employed in which two analyses were also conducted: a Cox regression with the 
baseline level of serum lymphocyte percentage as a covariate and a time-dependent Cox regression with the 
repeatedly measured serum lymphocyte percentage as a covariate.
To assess the effect of serum lymphocyte on lung function, the LMM model was fitted with age, gender, BMI, 
and smoking status (former or current) as additional covariates. Age, gender, BMI, smoking status (former or cur-
rent), and  FEV1% predicted were included as covariates in the LMM models for 6 MW distance, QOL, and in the 
Cox regression model. An adjusted P value < 0.05 was considered to indicate significance. SPSS version 25 (SPSS, 
Chicago, IL, USA) and SAS software, version 9.4 (SAS Institute, Inc., Cary, NC, USA) were used for all analyses.
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ethics approval and informed consent. This study was performed in accordance with the provisions 
of the Declaration of Helsinki. The study protocol was approved by the institutional review boards of the 17 
hospitals included in the KOLD Cohort (Asan Medical Center, Hanyang University Guri Hospital, Inje Univer-
sity Ilsan Paik Hospital, Bundangcha Hospital, Kangbook Samsung Medical Center, Ewha Womans University 
Mokdong Hospital, Kangwon National University Hospital, Korea University Anam Hospital, Seoul National 
University Hospital, Seoul National University Bundang Hospital, Hallym University Medical Center, Konkuk 
University Medical Center, Ajou University Hospital, National Medical Center, The Catholic University of Korea 
Seoul St Mary’s Hospital, The Catholic University of Korea Yeouido St Mary’s Hospital, Severance Hospital).
consent for publication. All study participants provided informed consent.
Results
Baseline characteristics. The baseline characteristics of the patients are shown in Table 1. Among the 
451 patients, 409 (90.7%) and 42 (9.3%) were categorized into normal and low lymphocyte groups, respec-
tively. The mean age, sex ratio, and proportion of patients with smoking status were similar between the groups. 
BMI (23.3 kg/m2 vs. 21.6 kg/m2; P = 0.009),  FEV1% predicted (55.7% vs. 47.1%; P = 0.001), FVC % predicted 
(91.0% vs. 84.9%; P = 0.030), and  FEV1/FVC (47.7% vs. 41.6%; P = 0.001) were significantly higher in the nor-
mal lymphocyte group. The proportion of GOLD III–IV was higher in the low lymphocyte group. The 6 MW 
distance (428 m vs. 360 m; P < 0.001) was longer and the SGRQ score (31.2 vs. 41.9; P < 0.001) was lower in the 
normal lymphocyte group. Mean follow-up duration was 6.0 years. Mortality during the follow-up period was 
significantly higher in the low lymphocyte group than that in the normal lymphocyte group (28.6% vs. 12.0%; 
P = 0.006). During the follow-up period, 58 (12.9%) patients expired. The causes of deaths consist of respiratory 
diseases (37.9%), cancer (24.1%), cardiovascular diseases (15.5%), others (5.2%), and unknown causes (17.2%). 
The serum lymphocyte percentage over the years did not vary and is depicted in Supplementary Fig. 1.
Pulmonary function, 6-min walking distance and quality of life. Table 2 shows the results of the 
regression analysis for the association of serum lymphocyte percentage with the pulmonary function, adjusted 
with age, sex, BMI, and smoking status. In the baseline analysis, a higher absolute serum lymphocyte percentage 
Table 1.  Baseline characteristics of the normal and low lymphocyte groups. Data are presented as numbers 
(percentages) or means ± standard deviation, unless otherwise indicated. FEV1 forced expiratory volume in 1 s, 
FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease, 6 MW 6-min walking, 
CAT COPD assessment test, SGRQ St. George’s respiratory questionnaire. a Normal lymphocyte group was 
defined as those with serum lymphocyte percentage 20 to 51%. b Low lymphocyte group was defined as those 
with serum lymphocyte percentage < 20%. c P value for comparison between COPD patients with GOLD I–II 
and those with GOLD III–IV.
Total (n = 451) Normal  lymphocytea (n = 409) Low  lymphocyteb (n = 42) P value
Sex, male 437 (96.9) 395 (96.6) 42 (100) 0.630
Age, years 67.5 ± 7.6 66.8 ± 7.3 66.6 ± 6.9 0.874
Body mass index, kg/m2 22.9 ± 3.2 23.3 ± 3.2 21.6 ± 3.6 0.009
Smoking status 0.401
 Current smoker 157 (34.8) 145 (35.5) 12 (28.6)
 Former smoker 294 (65.2) 264 (64.5) 30 (71.4)
Pulmonary function
 FEV1, L 1.65 ± 0.56 1.69 ± 0.55 1.32 ± 0.55  < 0.001
 FEV1, % predicted 54.9 ± 16.2 55.7 ± 15.7 47.1 ± 19.1 0.001
 FVC, L 3.50 ± 0.78 3.54 ± 0.78 3.12 ± 0.74 0.001
 FVC, % predicted 90.4 ± 17.6 91.0 ± 17.2 84.9 ± 19.9 0.030
 FEV1/FVC, % 47.1 ± 11.2 47.7 ± 11.0 41.6 ± 11.7 0.001
GOLDc 0.007
 GOLD I 24 (5.3) 22 (5.4) 2 (4.8)
 GOLD II 249 (55.3) 234 (57.4) 15 (35.7)
 GOLD III 151 (33.6) 134 (32.8) 17 (40.5)
 GOLD IV 26 (5.8) 18 (4.4) 8 (19.0)
6 MW distance, m 422 ± 88 428 ± 85 360 ± 97  < 0.001
CAT Score 13.8 ± 7.4 13.6 ± 7.3 15.8 ± 7.7 0.272
SGRQ score 32.2 ± 17.9 31.2 ± 17.5 41.9 ± 19.3  < 0.001
Number of exacerbation per year 0.48 ± 0.79 0.46 ± 0.78 0.67 ± 0.85 0.100
Follow-up duration, years 6.0 ± 3.9 6.1 ± 3.9 4.9 ± 3.1 0.052
Death during follow-up 58 (12.9) 46 (12.0) 12 (28.6) 0.006
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was related with a higher  FEV1% predicted and a higher  FEV1/FVC ratio, while these lung function param-
eters were similar between the normal and low lymphocyte groups. Clustered analysis showed that a higher 
absolute overall level of serum lymphocyte percentage was related with a higher  FEV1% predicted (estimated 
mean = 0.25%; P = 0.002) and a higher  FEV1/FVC ratio (estimated mean = 0.15%; P = 0.003). Low overall level 
lymphocyte group showed lower  FEV1% predicted (estimated mean =  − 5.70%; P = 0.001) and lower FVC % 
predicted (estimated mean =  − 5.63%; P = 0.005) than those of the normal lymphocyte group.
Table 3 shows the results of the regression analysis for the association of serum lymphocyte percentage 
with the 6 MW distance and quality of life indexes, adjusted with age, sex, BMI, smoking status, and baseline 
 FEV1. In the baseline analysis, a higher absolute percentage of serum lymphocytes was related with a longer 
6 MW distance and lower CAT and SGRQ scores. In the clustered analysis, a higher overall absolute percent-
age of serum lymphocytes was related with a longer 6 MW distance and lower CAT and SGRQ scores. Simi-
larly, in the between-group comparison, the low lymphocyte group showed a lower 6 MW distance (estimated 
mean =  − 41.31 m; P < 0.001), a higher CAT score (estimated mean = 2.62; P = 0.013), and a higher SGRQ score 
(estimated mean = 10.10; P < 0.001) in the clustered analysis.
frequent exacerbation and mortality. The serum lymphocyte percentage was not associated with fre-
quent exacerbations after adjustment for age, sex, BMI, smoking status, and baseline  FEV1 (Table 4).
Table 5 shows the results of the two analyses with multivariable Cox proportional hazard models: The Cox 
regression with the baseline level of serum lymphocyte percentage as a covariate and the time-dependent Cox 
Table 2.  Multivariate regression analysis for the effect of serum lymphocyte % on pulmonary function. 
Adjusted for age, gender, body mass index, and smoking status (current or former). FEV1 forced expiratory 
volume in 1 s, FVC forced vital capacity, SE standard error. a Normal lymphocyte group was defined as those 
with serum lymphocyte percentage 20 to 51%. b Low lymphocyte group was defined as those with serum 
lymphocyte percentage < 20%.
FEV1, % FVC, % FEV1/FVC, %
Estimated mean (SE) P value Estimated mean (SE) P value Estimated mean (SE) P value
Baseline lymphocyte, %
Lymphocyte, % 0.32 (0.09)  < 0.001 0.14 (0.09) 0.122 0.19 (0.06) 0.001
Lymphocyte groups
 Normal  lymphocytea Reference Reference Reference
 Low  lymphocyteb  − 8.51 (6.60) 0.198  − 12.42 (9.37) 0.185  − 1.18 (4.19) 0.778
Clustered analysis
Lymphocyte, % 0.25 (0.08) 0.002 0.12 (0.09) 0.293 0.15 (0.05) 0.003
Lymphocyte groups
 Normal  lymphocytea Reference Reference Reference
 Low  lymphocyteb  − 5.70 (1.71) 0.001  − 5.63 (1.98) 0.005  − 1.99 (1.21) 0.100
Table 3.  Multivariate regression analysis of the effect of serum lymphocyte % on 6-min walking distance and 
quality of life. Adjusted for age, sex, body mass index, smoking status (current or former), and baseline forced 
expiratory volume in 1 s, % predicted. SE standard error, 6 MW 6-min walking, CAT COPD assessment test, 
SGRQ St. George’s respiratory questionnaire. a Normal lymphocyte group was defined as those with serum 
lymphocyte percentage 20 to 51%. b Low lymphocyte group was defined as those with serum lymphocyte 
percentage < 20%.
6 MW distance, m CAT score SGRQ score
Estimated mean (SE) P value Estimated mean (SE) P value Estimated mean (SE) P value
Baseline lymphocyte, %
Lymphocyte, % 1.56 (0.45) 0.001  − 0.16 (0.04)  < 0.001  − 0.37 (0.10)  < 0.001
Lymphocyte groups
 Normal  lymphocytea Reference Reference Reference
 Low  lymphocyteb  − 32.26 (64.67) 0.618  − 1.37 (6.00) 0.820  − 1.53 (11.15) 0.891
Clustered analysis
Lymphocyte, % 1.88 (0.39)  < 0.001  − 0.16 (0.04)  < 0.001  − 0.42 (0.09)  < 0.001
Lymphocyte groups
 Normal  lymphocytea Reference Reference Reference
 Low  lymphocyteb  − 41.31 (8.94)  < 0.001 2.62 (1.05) 0.013 10.10 (2.02)  < 0.001
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regression with repeatedly measured serum lymphocyte percentage as a covariate. The results are adjusted for 
age, sex, smoking status, BMI, and baseline  FEV1. No significant relationship was observed.
Discussion
We investigated the serum lymphocyte percentage in Korean patients with COPD and its relationship with several 
clinical parameters of lung function, exercise capacity, QOL, exacerbation, and mortality. The major strength of 
this study is that it was a long-term multicenter study, which enhances the statistical reliability of the results. The 
present analysis showed that a low serum lymphocyte percentage is related with a lower lung function, a shorter 
6 MW distance, and worse quality of life, as shown by increased CAT and SGRQ scores.
The 6 MW distance is a simple and inexpensive test that provides a global and integrated response of both 
physical (pulmonary and nonpulmonary factors) and psychological factors in patients with  COPD22. The QOL 
is a composite concept that reflects the perception of an individual’s position within the living  context23. It is an 
important domain for measuring the impact of chronic  diseases24. Although acute exacerbation and the survival 
were not related with the serum lymphocyte percentage, the clinical significance of serum lymphocyte percentage 
in patients with COPD cannot be underestimated.
The present findings are in agreement with those of previous studies that attempted to use serum lymphocyte 
levels as a predictor in patients with COPD. Neutrophil to lymphocyte ratio (NLR) has shown to be an independ-
ent predictor of the prognosis in patients with  COPD25–28. However, the reason NLR is related with the prognosis 
and whether lymphocytes in particular are independently associated with the prognosis in patients with COPD 
remained unclear. Acanfora et al. had shown that in elderly patients with COPD, decreased serum lymphocyte 
levels were related with increased 3-year  mortality8.
Comparing our study with the previous study by Acanfora et al.8, the mortality did not rise as the serum 
lymphocyte percentage decreased in our study. In the study of Acanfora et al., patients were aged 65 years or older 
Table 4.  Multivariate regression analysis of the effect of serum lymphocyte % on frequent exacerbation. 
Adjusted for age, sex, body mass index, smoking status (current or former), and baseline forced expiratory 
volume in 1 s, % predicted. Frequent exacerbation was defined as having two or more exacerbations per year. 
CI confidence interval. a Normal lymphocyte group was defined as those with serum lymphocyte percentage 20 
to 51%. b Low lymphocyte group was defined as those with serum lymphocyte percentage < 20%.
Odds ratio (95% CI) P value
Baseline lymphocyte, %
Lymphocyte, % 0.98 (0.95–1.00) 0.056
Lymphocyte groups
 Normal  lymphocytea Reference
 Low  lymphocyteb 1.27 (0.71–2.29) 0.417
Clustered analysis
Lymphocyte, % 0.99 (0.97–1.01) 0.175
Lymphocyte groups
 Normal  lymphocytea Reference
 Low  lymphocyteb 1.00 (0.63–1.59) 0.989
Table 5.  Multivariable Cox’s proportional hazard analyses for relationship between serum lymphocyte % and 
mortality. Adjusted for age, sex, body mass index, smoking status (current or former), and baseline forced 
expiratory volume in 1 s, % predicted. CI confidence interval. a Normal lymphocyte group was defined as 
those with serum lymphocyte percentage 20 to 51%. b Low lymphocyte group was defined as those with serum 
lymphocyte percentage < 20%.
Hazards ratio (95% CI) P value
Baseline lymphocyte, %
Lymphocyte, % 0.99 (0.96–1.03) 0.749
Lymphocyte groups
 Normal  lymphocytea Ref
 Low  lymphocyteb 1.27 (0.66–2.43) 0.478
Overall level of lymphocyte, %
Lymphocyte, % 0.99 (0.95–1.05) 0.937
Lymphocyte groups
 Normal  lymphocytea Ref
 Low  lymphocyteb 1.92 (0.77–4.80) 0.163
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and had severe or very severe air flow limitation, suggesting a more severe COPD status than that of patients in 
our study. Furthermore, our study analyzed a longer follow-up period of mean 6 years for mortality. The propor-
tion of death during the total follow-up period was significantly higher in the low lymphocyte group than that 
in the high lymphocyte group in our study as well.
The prognostic value of the lymphocyte count has been evaluated in cardiovascular  diseases29–32. A low lym-
phocyte count was related with an increased risk for myocardial infarction and death in patients with acute chest 
pain, a non-diagnostic electrocardiogram, and normal troponin levels. In the English general population without 
pre-existing cardiovascular disease, low lymphocyte counts were associated with an increased short-term inci-
dence of heart failure and coronary  death31. The authors described the relationship of lymphopenia and cardiac 
events as a result of systemic stress and inflammatory activation, driven by tissue ischemia and oxidative stress.
It has been long known that chronic inflammation is a key pathogenic element in COPD and that lymphocytes 
play a crucial role in the pathogenesis of  COPD9,32. In the histopathologic study, the bronchioles are obstructed 
by fibrosis and infiltration with macrophages and T  lymphocytes1. In severe COPD, bronchoalveolar lavage or 
induced sputum shows a more marked increase in macrophages and  neutrophils1, which may result in decreased 
relative percentage of lymphocytes. Moreover, lymphopenia may be a sign of an impaired immune system, 
increasing the risk of infection, although lymphopenia was not associated with COPD exacerbation in our study 
where moderate or severe exacerbation were evaluated. However, lymphocytes would be a comprehensive indica-
tor of the general health status as a low lymphocyte count was related with heart failure, chronic kidney disease, 
atrial fibrillation, and COPD in patients admitted for acute heart  failure27. Elderly adults have a lower lympho-
cyte level than that of young adults and apoptosis is associated with cellular  depletion33. However, lymphopenia 
would be the result of a systemic response to psychological and physiological stress. Increased production of 
cortisol, catecholamines, and proinflammatory cytokines may decrease the production of lymphocytes, increase 
the apoptosis, or make redistribution of  lymphocytes30,34.
Another reason for our results may be that a low lymphocyte level is also related with malnutrition. The 
relationship between malnutrition and lymphocytopenia is well  known35, and lymphocytes are included in the 
prognostic nutritional index, a nutritional marker. Patients with stable COPD generally have a normal lympho-
cyte count, but lymphopenia occurs during acute weight loss in the setting of severe illness or acute respiratory 
failure. Refeeding and weight gain in patients with COPD with recent weight loss in a state of mild malnutrition 
were associated with a significant increase in the lymphocyte  count36. BMI is another essential marker for assess-
ment of the nutritional status in COPD; however, a low lymphocyte level was significantly associated with worse 
exercise capacity and quality of life even after adjustment with BMI in this  analysis37.
Our study has several limitations. First, the proportion of patients in the low lymphocyte group was relatively 
small compared to that of patients in the normal lymphocyte group. However, the repeated measurements over 
a long-term period are the strength of this study. Second, KOLD cohort recruited COPD patients with smok-
ing history, which led to male dominance in the study population. In Korea, smoking rate of women is low at 
5–6%38. Therefore, this study may not represent the general pool of patients with COPD. Smoking is known to 
reduce the serum lymphocyte  level39. Therefore, current or former smoking status was included as a co-variate 
in the analysis. Third, other conditions that might influence the serum lymphocyte level were not included in 
the analysis, such as a history of infection or medication. Fourth, lymphocyte sub-types, such as B cells and T 
cells, were not further investigated; thus, the respective prognostic role of deficits of the cellular and humoral 
immunity could not be assessed.
In conclusion, this COPD cohort study included simultaneously repeated measurement of serum lymphocyte 
percentage and clinical consequences every year.
Our study showed that a lower percentage of lymphocytes in the serum is related with several negative clinical 
outcomes in COPD. In patients with a low serum lymphocyte level, the pulmonary function was lower, the 6 MW 
distance was shorter, and the QOL was worse. Serum lymphocyte percentage could be a simple, intuitive, repro-
ducible, widely available, and inexpensive predictive marker for variable clinical outcomes in patients with COPD.
Data availability
The datasets used and/or analyzed are available from corresponding author upon reasonable request.
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